Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders

Byron Cryer, Douglas A. Drossman, William D. Chey, Lynn Webster, Sepideh Habibi, Martin Wang

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


Background: Lubiprostone is a ClC-2 chloride channel activator approved for the treatment of chronic idiopathic constipation (CIC) and opioid-induced constipation (OIC) in adults and irritable bowel syndrome with constipation (IBS-C) in women. Lubiprostone is generally well tolerated, with nausea being the most common adverse event. Aims: To characterize nausea with lubiprostone using pooled results from clinical studies in patients with CIC, OIC, or IBS-C. Methods: Data from three 3- and 4-week placebo-controlled studies and three long-term open-label studies were pooled for the CIC analysis. The OIC and IBS-C analyses each used pooled data from three 12-week placebo-controlled studies and one 36-week open-label extension study. Results: The populations included the following numbers of patients: CIC, 316 (placebo) and 1113 (lubiprostone 24 mcg twice daily [BID]); OIC, 652 (placebo) and 889 (lubiprostone 24 mcg BID); and IBS-C, 435 (placebo) and 1011 (lubiprostone 8 mcg BID). The incidence of nausea in lubiprostone-treated patients ranged from 11.4 to 31.1%, with the highest incidence in patients with CIC. Among patients with any nausea, most reported only mild or moderate severity (96.5–99.1% across indications) and only one event (83.6–88.7%); most events occurred within the first 5 days of treatment. Conclusions: Nausea was the most common adverse event following the treatment with lubiprostone. Event rates varied by indication and dose, and the majority of nausea adverse events were mild to moderate in severity. Nausea events predominantly occurred early in the treatment period in all of the pooled study populations.

Original languageEnglish (US)
Pages (from-to)3568-3578
Number of pages11
JournalDigestive Diseases and Sciences
Issue number12
StatePublished - Dec 1 2017


  • Chronic idiopathic constipation
  • Irritable bowel syndrome with constipation
  • Lubiprostone
  • Nausea
  • Opioid-induced constipation

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology


Dive into the research topics of 'Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders'. Together they form a unique fingerprint.

Cite this